Multiple Sclerosis Centre of Catalonia
Cemcat (the Multiple Sclerosis Centre of Catalonia) is working to advance diagnosis in the Neurology and Neuroimmunology Department. At the same time, it uses neuropsychology to detect and treat cognitive and emotional disorders associated with the illness. In parallel, throughout treatment, it uses neurorehabilitation as an important resource.
With a philosophy of people-centred healthcare and with patient-agreed objectives, treatment can be personalised. In short, it is a matter of improving the quality of life of patients according to their needs and decisions.
Healthcare activities include:
- medical activity in external consultations
- nursing care at the Day Hospital related to administering treatment
- neuropsychological and emotional patient assessments
Over more than 20 years, Cemcat has systematically collected data on the evolution of patients who have been prescribed treatment for multiple sclerosis in the centre. This allows these people to be monitored and the results on the effectiveness of new drugs to be rapidly assessed.
One of Cemcat’s innovations is the Independent Life Laboratory, where occupational therapy is performed. The aim is to help patients to return to normal life in a 35 m2 space, which reconstructs an accessible and automated apartment. Patients thus learn to adapt their movements to their surroundings.
Where to find it
The Multiple Sclerosis Centre of Catalonia, Cemcat, is a pioneering centre in the treatment of this neurodegenerative pathology and is led by Dr. Xavier Montalban. A leader in applying an overall view of patients and offering the most advanced treatments available.
The winning proposal for the transformation of the Vall d’Hebron Campus is the project directed by Jordi Badia, Antoni Ubach and Miquel Espinet. The project presented by the architects includes a new research building for the Vall d'Hebron Research Institute, with an expandable area of 5,000 m2 and a budget of €15 million funded by ERDF (European Regional Development Fund).